Tampa, Florida 33606

  • acquired Bacterial Pneumonia


This is a phase 2/3, randomized, open-label, active control, multi-center study to assess the safety and efficacy of solithromycin in children and adolescents with community-acquired bacterial pneumonia (CABP).

Study summary:

Subjects who meet all inclusion/exclusion criteria and sign the informed consent/assent were enrolled. Subjects were randomized to receive solithromycin or a comparator antibiotic, administered IV and/or by mouth (PO) based on weight and age. Subjects were treated daily for 5 to 7 days with oral solithromycin and 5 to 7 days with IV or IV-to-oral solithromycin. Subjects were treated for 5 to 10 days with comparator antibiotics. Subjects received safety and efficacy assessments during and after treatment.


Inclusion Criteria: - History of and/or documented fever (rectal, ear, or oral temperature ≥38°C or axillary temperature ≥37.5°C) or hypothermia (rectal, ear, or oral temperature <35°C or axillary temperature <34.5°C) - Chest radiograph infiltrates consistent with bacterial pneumonia (or pneumonia caused by atypical bacterial agents); if a subject is outpatient and starting on oral therapy, a radiograph is not required. - Presence of at least 2 of the following signs or symptoms: - Cough - Difficulty breathing - Production of purulent sputum - Chest pain - Grunting - Hypotension - Tachycardia, defined as follows: 2 months to <24 months: ≥160 beats/min 24 months to <10 years: ≥140 beats/min - 10 years: ≥100 beats/min - Tachypnea, defined as follows: 2 months to <12 months: ≥50 breaths/min 12 months to <5 years: ≥40 breaths/min - 5 years: ≥20 breaths/min - Physical exam consistent with pulmonary consolidation - Presence of at least 1 of the following: - Leukocytosis (≥12,000 white blood cells [WBC]/mm3) - Leukopenia (<5000 WBC/mm3) - ≥10% immature neutrophils (bands) regardless of total peripheral WBC - Elevated inflammatory markers (C-reactive protein or procalcitonin) - Oxygen saturation <97% on room air - Organism consistent with a typical respiratory pathogen identified Exclusion Criteria: - Ventilator-associated or hospital-acquired pneumonia - >48 hours of systemic antibacterial therapy - confirmed or suspected bacterial meningitis - breast-feeding females - positive pregnancy test



Primary Contact:

Principal Investigator
Michael Cohen-Wolkowiez, MD, PhD
Duke Clinical Research Institute

Backup Contact:


Location Contact:

Tampa, Florida 33606
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: March 26, 2020

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.